NEW YORK – Healthcare informatics firm Echelon Diagnostics said Tuesday that it is collaborating with oncology diagnostic developer Oncocyte to develop analytical software that can scale to support the commercial expansion of Oncocyte's tests.
Based in Reno, Nevada, Echelon provides AI imaging and big data solutions supporting a range of molecular diagnostic technologies.
Irvine, California-based Oncocyte has built a pipeline of oncology diagnostic assays through acquisitions of various other companies and IP. Its first commercial offering, DetermaRx, is a 14-gene, RNA-based assay designed to identify patients with early-stage, non-small cell lung cancer who may benefit from adjuvant chemotherapy.
"EchelonDx was the right partner to help us build the software solution that allows us to scale and launch our proprietary tests worldwide in a manner that ensures … uniform and accurate testing," Oncocyte CSO Doug Ross said in a statement.
Financial terms of the agreement were not disclosed.